Julie Forman-Kay is program head in molecular medicine at the Hospital for Sick Children in Toronto, Canada. She received her B.Sc. in chemistry from the Massachusetts Institute of Technology and her Ph.D. in molecular biophysics andd biochemistry from Yale University. The major focus of her lab is to provide biological insights into how dynamic properties of proteins are related to function and methodological tools to enable better understanding of dynamic and disordered states. Most recently, her lab has probed the biophysics of protein phase separation and how it regulates cellular condensates and biological function.
Julie Forman-Kay
Program head
Hospital for Sick Children
From this contributor
How microscopic ‘condensates’ in cells might contribute to autism
A controversial idea about how cells compartmentalize their contents into droplets — like beads of oil in water — could be key to understanding autism, says Julie Forman-Kay.
How microscopic ‘condensates’ in cells might contribute to autism
Explore more from The Transmitter
The Transmitter’s most-read neuroscience book excerpts of 2025
Books by Nachum Ulanovsky, Nicole Rust, and Andrew Iwaniuk and Georg Striedter made the list of some of the year's most engaging neuroscience titles.
The Transmitter’s most-read neuroscience book excerpts of 2025
Books by Nachum Ulanovsky, Nicole Rust, and Andrew Iwaniuk and Georg Striedter made the list of some of the year's most engaging neuroscience titles.
Neuroscience’s leaders, legacies and rising stars of 2025
Here are seven stories from the past year about some of the field’s most engaging figures.
Neuroscience’s leaders, legacies and rising stars of 2025
Here are seven stories from the past year about some of the field’s most engaging figures.
The Transmitter’s top news articles of 2025
Check out some of our most-read stories, covering neuroscience funding and policy changes in the United States, and methodological issues in high-profile neuroscience papers.
The Transmitter’s top news articles of 2025
Check out some of our most-read stories, covering neuroscience funding and policy changes in the United States, and methodological issues in high-profile neuroscience papers.